Search results
Learn about BMS's latest cell therapy milestone, its commitment to address health inequities, its scientific research approaches, and its ESG report. Find out how to join, invest, or access clinical trial and medical information.
- Careers
At Bristol Myers Squibb, your work helps people prevail over...
- Help Paying for Medicines
In 2015, Bristol Myers Squibb provided more than $694...
- Contact Us
Contact Bristol Myers Squibb through our contact form,...
- About Us
We promote health equity and seek to improve the health...
- Patients & Caregivers
At Bristol Myers Squibb, we are committed to helping you get...
- Investor Relations
Forward-looking statements contained on this website should...
- Events and Presentations
Forward-looking statements contained on this website should...
- Our Company
At Bristol Myers Squibb, we believe in the power of science...
- Careers
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
Bristol Myers Squibb is a leading biopharma company that discovers, develops and delivers innovative medicines for serious diseases. Learn about its mission, values, leadership, sustainability, responsibility and achievements.
Bristol Myers Squibb focuses on developing new medicines to address the unmet medical needs of patients with serious diseases. Explore comprehensive information about our products including dosage and safety information.
Feb 4, 2022 · NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’s pipeline that further progressed the company’s portfolio renewal.
Bristol Myers Squibb to Participate in Upcoming Investor Conferences. 05/06/2024. European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... 05/06/2024.
Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.